CD40 Agonist and PD-1 Inhibitor in HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: PD-1inhibitor - LVGN 3616; Drug: CD 40 Agonist - LVGN 7409 Sponsors: University of Pennsylvania Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | HNSCC | Research | Skin Cancer | Squamous Cell Carcinoma | University of Pennsylvania